The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

Journal of the American College of Cardiology

Volumn 35, Issue 7, 2000, Pages 1737-1744

  Silverberg, Donald S ^a   Wexler, Dov ^a   Blum, Miriam ^a   Keren, Gad ^a   Sheps, David ^a   Leibovitch, Eyal ^a   Brosh, David ^a   Laniado, Shlomo ^a   Schwartz, Doron ^a   Yachnin, Tatyana ^a   Shapira, Itzhak ^a   Gavish, Dov ^a   Baruch, Ron ^a   Koifman, Bella ^a   Kaplan, Carl ^a   Steinbruch, Shoshana ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; HEMOGLOBIN; IRON; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; IRON THERAPY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 0034128813     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00613-6     Document Type: Article

References (61)

1. Haber H.L., Leavy J.A., Kessler P.D., et al. The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med. 324:1991;353-358.
2. Rich M.W., Beckham V., Wittenberg C., et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 333:1995;1190-1195.
3. Rich M.W., Shah A.S., Vinson J.M., et al. Iatrogenic congestive heart failure in older adults clinical course and prognosis. J Am Geriatr Soc. 44:1996;638-643.
4. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30 Suppl:193-240.
5. Maeda K., Tanaka Y., Tsukano Y., et al. Multivariate analysis using a linear discriminant function for predicting the prognosis of congestive heart failure. Jpn Circ J. 46:1982;137-142.
6. Volpe M., Tritto C., Testa U., et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 74:1994;468-473.
7. Anand I.S., Chandrashekhar Y., Ferrari R., Poole-Wilson P.A., Harris P. Pathogenesis of edema in chronic anemia studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br Heart J. 70:1993;357-362.
8. Low I., Grutzmacher P., Bergmann M., Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol. 31:1989;26-30.
9. Low-Friedrich I., Grutzmacher P., Marz W., Bergmann M., Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol. 11:1991;54-60.
10. Goldberg N., Lundin A.P., Delano B., Friedman E.A., Stein R.A. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 124:1992;424-427.
11. Foley R.N., Parfrey P.S., Morgan J., et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation (abstr). J Am Soc Nephrol. 9:1998;208.
12. Linde T., Wikstrom B., Andersson L.G., Danielson B.G. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Scand J Urol Nephrol. 30:1996;115-120.
13. Heart failure: management of patients with left-ventricular systolic dysfunction. Quick reference guide for clinicians. No. 11. AHRCPR Publication No. 94-0613. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
14. Ghali J.K., Kadakia S., Cooper R., Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 148:1988;2013-2016.
15. Opasich C., Febo O., Riccardi P.G., et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 78:1996;354-357.
16. Michaelsen A., Konig G., Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 80:1998;437-441.
17. Packer M., Cohn J.N., Abraham W.T., et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 83:(Suppl 2A):1999;1-38.
18. Massie B.M., Shah N.B. The heart failure epidemic magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol. 11:1996;221-226.
19. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J. 18:1997;208-225.
20. Senni M., Redfield M.M. Congestive heart failure in elderly patients. Mayo Clin Proc. 72:1997;453-460.
21. Silverberg D.S., Blum M., Peer G., Kaplan E., Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron. 72:1996;413-417.
22. Silverberg D.S., Blum M., Agbaria Z., et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int. 55:(Suppl 69):1999;79-85.
23. Hochberg Y. Some conservative generalizations of the T-methods in simultaneous inference. J Multivar Anal. 4:1974;224-234.
24. Carson J.L. Morbidity risk assessment in the surgically anemic patient. Am J Surg. 170:(Suppl):1995;32-36.
25. Carson J.L., Duff A., Poses R.M., et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 348:1996;1055-1060.
26. Wald M., Gutnisky A., Borda E., Sterin B.L. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron. 71:1995;190-196.
27. Reis S.E., Holubkov R., Edmundowicz D., et al. Treatment of patients admitted to the hospital with congestive heart failure specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 30:1997;733-738.
28. Anand I.S., Chugh S.S. Mechanisms and management of renal dysfunction in heart failure. Curr Opin Cardiol. 12:1997;251-258.
29. Yoshida H., Yashiro M., Liang P., et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int. 53:1998;880-891.
30. Roth D., Smith R.D., Schulman G., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 24:1994;777-784.
31. Scharer K., Klare B., Braun A., Dressel P., Gretz N. Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. Acta Paediatr. 82:1993;953-958.
32. Lopez-Gomez J.M., Jofre R., Moreno F., Verde E., Valderrabano F. rHuEPO before dialysis and in dialysed patients. Nephrol Dial Transplant. 10:(Suppl 6):1995;31-35.
33. Kuriyama S., Tomonari H., Yoshida H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 77:1997;176-185.
34. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 339:1998;584-590.
35. Macdougall I.C., Ritz E. The normal hematocrit trial in dialysis patients with cardiac disease are we any less confused about target hemoglobin? Nephrol Dial Transplant. 13:1998;3030-3033.
36. Silverberg D., Blum M., Peer G., Iaina A. Anemia during predialysis period a key to cardiac damage in renal failure. Nephron. 80:1998;1-5.
37. Locatelli F., Conte F., Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 13:1998;1642-1644.
38. Ma J.Z., Ebben J., Xia H., Collins A.J. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 10:1999;610-619.
39. Macdougall I.C., Tucker B., Thompson J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 50:1996;1694-1699.
40. Koch K.M., Koene R.A.P., Messinger D., Quarder O., Scigalla P. The use of Epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol. 44:1995;201-208.
41. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant. 10:(Suppl 2):1995;74-79.
42. Fishbane S., Frei G.L., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 26:1995;41-46.
43. Silverberg D.S., Iaina A., Peer G., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 27:1996;234-238.
44. Schwengel R.H., Gottlieb S.S., Fisher M.L. Protein-energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol. 73:1994;908-910.
45. King D., Smith M.L., Chapman T.J., Stockdale H.R., Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 25:1996;144-149.
46. Weil J., Colin J.D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J. 310:1995;827-830.
47. Silagy C.A., McNeil J.J., Donnan G.A., et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 54:1993;84-89.
48. Donnelly S.M., Posen G.A., Ali M.A. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med. 14:1991;271-276.
49. Goch J., Birgegard G., Danielson B.G., Wikstrom B. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron. 73:1996;403-406.
50. Kooistra M.P., Niemantsverdriet E.C., van Es A., et al. Iron absorption in erythropoietin-treated haemodialysis patients effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant. 13:1998;828-828.
51. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
52. Herrera-Garza E.H., Stetson S.J., Cubillos-Garzon A., Vooletich M.T., Farmer J.A., Torre-Amione G. Tumor necrosis factor. A mediator of disease progression in the failing human heart. Chest. 115:1999;1170-1174.
53. Goicoechea M., Martin J., de Sequera P., et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Intern. 54:1998;1337-1343.
54. Feelders R.A., Vreugdenhil G., Eggermont A.M.M., Kuiper-Kramer P.A., Van Eijk H.G., Swaak A.J.G. Regulation of iron metabolism in the acute-phase response interferon and tumour necrosis factor induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 28:1998;520-527.
55. Horl W.H. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant. 14:(Suppl 2):1999;50-60.
56. Albitar S., Genin R., Fen-Chong M., Serveauz M.-O., Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant. 13:1998;1206-1210.
57. Erturk S., Nergizoglu G., Ates K., et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant. 14:1999;1912-1916.
58. Fonarow G.C., Stevenson L.W., Walden J.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 30:1997;725-732.
59. Cline C.M.J., Israelsson B.Y.A., Willenheimer R.B., Broms K., Erhardt L.R. Cost effective management programme for heart failure reduces hospitalisation. Heart. 80:1998;442-446.
60. US Renal Data System. Comorbid conditions and correlations with mortality risk among 3,999 incident hemodialysis patients. Am J Kidney Dis 1992;20:32-8.
61. Elhalel-Dranitzki M., Rubinger D., Moskovici A., et al. CAPD to improve quality of life in patients with refractory heart failure. Nephrol Dial Transplant. 13:1998;3041-3042.